Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer AND Cisplatin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    911 result(s) found for: Cancer AND Cisplatin. Displaying page 31 of 46.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    EudraCT Number: 2009-014858-15 Sponsor Protocol Number: TRC112765 Start Date*: 2010-10-27
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR),...
    Medical condition: chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) GR (Completed) FI (Completed) HU (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009894-88 Sponsor Protocol Number: NCT-2008-11-01-1015 Start Date*: 2009-09-17
    Sponsor Name:University Hospital of Heidelberg
    Full Title: Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial
    Medical condition: Gastric Cancer, cancer of the oesophago-gastric junction, esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017758 Gastric cancer LLT
    9.1 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004157-16 Sponsor Protocol Number: CABinMET Start Date*: 2018-02-21
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
    Medical condition: Stage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019384-11 Sponsor Protocol Number: EFC10259 Start Date*: Information not available in EudraCT
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multinational, randomized, double blind, controlled phase II trial of ombrabulin with taxane and platinum combination administered every three weeks, in first line treatment of patients with meta...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004260-36 Sponsor Protocol Number: MS100070_0160 Start Date*: 2018-03-12
    Sponsor Name:Associació Per a la Recerca Oncològica (APRO)
    Full Title: Phase II multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with unresectable or...
    Medical condition: Unresectable or metastatic urothelial carcinoma in patients without prior systemic therapy and who are ineligible to receive cisplatin-based therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005537-32 Sponsor Protocol Number: D419QC00007 Start Date*: 2021-07-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Ca...
    Medical condition: Extensive-stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) IT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001016-21 Sponsor Protocol Number: AGMT_ECa Start Date*: 2008-08-28
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinom
    Medical condition: Unbehandeltes, histologisch gesichertes, nicht-metastasiertes Ösophaguskarzinom (Plattenepithelkarzinom)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056104 Squamous cell carcinoma of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017437-22 Sponsor Protocol Number: CCPS5959 Start Date*: 2010-02-24
    Sponsor Name:AZIENDA OSPEDALIERA DI PERUGIA
    Full Title: MANAGEMENT OF PRIMARY AND SECUNDARY PERITONEAL CARCINOMATOSIS FROM COLO-RECTAL CANCER, RECURRENT OVARIAN CANCER AND ABDOMINAL SARCOMATOSIS BY CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL...
    Medical condition: Peritoneal carcinomatosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061344 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005745-20 Sponsor Protocol Number: IPR/26 Start Date*: 2013-03-24
    Sponsor Name:MolMed S.p.A.
    Full Title: NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer
    Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002512-10 Sponsor Protocol Number: Magen-Studie 4 Start Date*: 2006-09-11
    Sponsor Name:An-Institut für Qualitätssicherung in der operativen Medizin gGmbH
    Full Title: Offene, unkontrollierte Phase II-Studie zur Überprüfung der Wirksamkeit und Verträglichkeit einer Kombination mit Cisplatin/Docetaxel und Cetuximab bei Patienten mit lokal fortgeschrittenem oder ...
    Medical condition: metastasiertes Adenokarzinom des Magens oder gastroösophagalen Übergangs
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042090 Stomach carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004430-96 Sponsor Protocol Number: 201600107 Start Date*: 2017-12-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk
    Medical condition: Testicular cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003767-23 Sponsor Protocol Number: EGF105884 Start Date*: 2006-07-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in S...
    Medical condition: Stage III, IVa, IVb Squamous Cell Carcinoma of the Head & Neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002424-41 Sponsor Protocol Number: OGX-427-02 Start Date*: 2011-11-22
    Sponsor Name:OncoGenex Technologies, Inc.
    Full Title: A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
    Medical condition: Metastatic or locally inoperable, advanced (T4b, N2, N3 or M1) transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003573-50 Sponsor Protocol Number: 20060439 Start Date*: 2008-02-18
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in ...
    Medical condition: Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063916 Metastatic gastric cancer LLT
    9.1 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GB (Completed) FR (Completed) AT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003780-35 Sponsor Protocol Number: AIO-TRK-0221 Start Date*: 2019-04-01
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhib...
    Medical condition: Non-small cell lung cancer stage IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029664 Non-small cell neoplasms malignant of the respiratory tract cell type specified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012413-21 Sponsor Protocol Number: I08011 Start Date*: 2009-08-04
    Sponsor Name:CHU Limoges
    Full Title: Etude de phase II évaluant un traitement par cisplatine et vinorelbine orale administrés de façon hebdomadaire et radiothérapie concomitante chez le sujet âgé indépendant atteint de cancer broncho-...
    Medical condition: No small cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029519 Non-small cell lung cancer stage III LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005051-42 Sponsor Protocol Number: PR016-CLN-pro003 Start Date*: 2008-03-20
    Sponsor Name:Protherics Salt Lake City, Inc
    Full Title: A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with locali...
    Medical condition: localized or loco-regional esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-009035-30 Sponsor Protocol Number: CP15-0802 Start Date*: 2009-10-27
    Sponsor Name:ImClone LLC
    Full Title: Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refrac...
    Medical condition: Platinium-refractory or Platinium-resistant Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003584-53 Sponsor Protocol Number: Debio1347-201 Start Date*: 2019-02-05
    Sponsor Name:Debiopharm International SA
    Full Title: A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3
    Medical condition: Three cohorts will be included consisting of subjects with biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and all other solid tumor histologies not included in Cohorts 1-2 such as NS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GR (Completed) AT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DK (Completed) NO (Completed) BG (Completed) FI (Completed) ES (Temporarily Halted) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011327-31 Sponsor Protocol Number: GECP0901PHALCIS Start Date*: 2009-08-18
    Sponsor Name:Grupo Español de Cáncer de Pulmón
    Full Title: Estudio de pemetrexed y cisplatino como tratamiento de primera línea en pacientes con cáncer de pulmón no escamoso, avanzado: estudio farmacogenómico en fase IIA (Study of pemetrexed disodium plus...
    Medical condition: Cáncer de Pulmón no microcítico (Non-small lung cancer, non squamous)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 07:12:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA